中国临床药理学杂志Issue(12)：1109-1111,3.DOI:10.13699/j.cnki.1001-6821.2015.12.010
利妥昔单抗联合改良 CHOP方案治疗非霍奇金淋巴瘤的临床疗效及安全性评价
Rituximab combined with CHOP chemotherapy regimen in the treatment of relapsing non-hodgkin′s lymphoma
摘要
Abstract
Objective To assess the effects and safety of rituximab com-bined with CHOP chemotherapy regimen ( 600 mg・ m-2 cytoxan on day 1+1.4 mg・ m-2 vinblastine on day 1+prednisone 60 mg on day 1 to 5+25 mg・ m-2 adriamycin on day 1 ) in the treatment of relapsing non-hodgkin′s lymphoma.Methods A total of 62 cases of relapsing non-hodgkin′s lymphoma were divided into experiment group ( n=29 ) and control group ( n =33 ) .Patients in the control group were given CHOP regimen combined with 10 mg・ m-2 bleomycin on day 1 and 5 mg・ m-2 etoposide on day 1 to 3.Patients in experiment group were given 375 mg・ m-2 rituximab 2 days before CHOP chemotherapy.All of the patients underwent 4 to 6 cycles of chemotherapy (21 days was a cy-cle).The clinical effects and adverse reactions were evaluated between the two groups.Results The objective response rate were 93.10%and 75.76%in experiment and control group respectively ( P <0.05 ) .The mean complete response time were ( 14.6 ±3.8 ) months in experiment group, higher than(6.4 ±2.2) months in control group( P<0.05).The main adverse reaction in two groups were not statistically different (P>0.05).Conclusion Rituximab combined with CHOP chemothera-py regimen can improve the clinical efficacy and complete response time on patients with relapsing non-hodgkin′s lymphoma.关键词
利妥昔单抗/改良CHOP方案/非霍奇金淋巴瘤/临床疗效Key words
rituximab/CHOP regimen/non-hodgkin′s lymphoma/clinical efficacy分类
医药卫生引用本文复制引用
张燕萍,周晓慧,张丽,马光丽..利妥昔单抗联合改良 CHOP方案治疗非霍奇金淋巴瘤的临床疗效及安全性评价[J].中国临床药理学杂志,2015,(12):1109-1111,3.基金项目
中医药行业科研专项基金资助项目 （）
